Moderna Stock Performance
| MRNA Stock | USD 34.71 0.09 0.26% |
The company secures a Beta (Market Risk) of 1.25, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Moderna will likely underperform. At this point, Moderna has a negative expected return of -0.0288%. Please make sure to verify Moderna's skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Moderna performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Moderna has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Moderna is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.26 | Five Day Return 0.84 | Year To Date Return (17.36) | Ten Year Return 86.61 | All Time Return 86.61 |
1 | Disposition of 1453 shares by James Mock of Moderna subject to Rule 16b-3 | 01/03/2025 |
2 | Acquisition by Hoge Stephen of 523 shares of Moderna subject to Rule 16b-3 | 01/31/2025 |
3 | AIM Vaccines mRNA Shingles Vaccine Submits Clinical Application to the U.S. | 02/25/2025 |
4 | Moderna Inc Secures UK Approval for RSV Vaccine mRESVIA | 02/28/2025 |
5 | Moderna wins patent lawsuit against BioNTechPfizer in German court | 03/05/2025 |
6 | Why You Shouldnt Be Buying MRNA Stock At 35 | 03/06/2025 |
7 | The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals | 03/07/2025 |
8 | BioNTech Surpasses Q4 Revenue Estimates | 03/10/2025 |
9 | Customer Intelligence Summit Singapore, 8 April 2025 at Marina Bay Sands | 03/11/2025 |
10 | 3 Reasons MRNA is Risky and 1 Stock to Buy Instead | 03/12/2025 |
11 | Deliveries of Chinese Communist Party newspaper to MPs could be stopped | 03/13/2025 |
| Begin Period Cash Flow | 2.9 B |
Moderna |
Moderna Relative Risk vs. Return Landscape
If you would invest 3,836 in Moderna on December 18, 2024 and sell it today you would lose (365.00) from holding Moderna or give up 9.52% of portfolio value over 90 days. Moderna is currently does not generate positive expected returns and assumes 5.3386% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Moderna, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Moderna Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Moderna's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Moderna, and traders can use it to determine the average amount a Moderna's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0054
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MRNA |
Estimated Market Risk
| 5.34 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Moderna is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Moderna by adding Moderna to a well-diversified portfolio.
Moderna Fundamentals Growth
Moderna Stock prices reflect investors' perceptions of the future prospects and financial health of Moderna, and Moderna fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Moderna Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (1.29) % | ||||
| Current Valuation | 7.11 B | ||||
| Shares Outstanding | 386.62 M | ||||
| Price To Earning | 6.37 X | ||||
| Price To Book | 1.23 X | ||||
| Price To Sales | 4.14 X | ||||
| Revenue | 3.24 B | ||||
| Gross Profit | (2.77 B) | ||||
| EBITDA | (3.39 B) | ||||
| Net Income | (3.56 B) | ||||
| Cash And Equivalents | 8.35 B | ||||
| Cash Per Share | 21.73 X | ||||
| Total Debt | 710 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 2.10 X | ||||
| Book Value Per Share | 28.24 X | ||||
| Cash Flow From Operations | (3 B) | ||||
| Earnings Per Share | (9.28) X | ||||
| Market Capitalization | 13.38 B | ||||
| Total Asset | 14.14 B | ||||
| Retained Earnings | 10.04 B | ||||
| Working Capital | 5.89 B | ||||
| Current Asset | 850 K | ||||
| Current Liabilities | 2.44 M | ||||
About Moderna Performance
By analyzing Moderna's fundamental ratios, stakeholders can gain valuable insights into Moderna's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Moderna has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Moderna has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 29.17 | 27.71 | |
| Return On Tangible Assets | (0.25) | (0.24) | |
| Return On Capital Employed | (0.33) | (0.31) | |
| Return On Assets | (0.25) | (0.24) | |
| Return On Equity | (0.33) | (0.31) |
Things to note about Moderna performance evaluation
Checking the ongoing alerts about Moderna for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Moderna help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Moderna generated a negative expected return over the last 90 days | |
| Moderna has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 3.24 B. Net Loss for the year was (3.56 B) with loss before overhead, payroll, taxes, and interest of (2.77 B). | |
| Moderna currently holds about 8.35 B in cash with (3 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.73. | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from independent.co.uk: Deliveries of Chinese Communist Party newspaper to MPs could be stopped |
- Analyzing Moderna's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Moderna's stock is overvalued or undervalued compared to its peers.
- Examining Moderna's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Moderna's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Moderna's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Moderna's stock. These opinions can provide insight into Moderna's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |